The influence of prophylactic factor VIII in severe haemophilia A

被引:15
|
作者
Gissel, M. [1 ]
Whelihan, M. F. [1 ]
Ferris, L. A. [1 ]
Mann, K. G. [1 ]
Rivard, G. E. [2 ]
Brummel-Ziedins, K. E. [1 ]
机构
[1] Univ Vermont, Dept Biochem, Colchester, VT USA
[2] Univ Montreal, CHU Ste Justine, Montreal, PQ, Canada
关键词
factor VIII; factor XIII; haemophilia; inhibitory antibody; prophylaxis; thrombin generation; RECOMBINANT FACTOR VIIA; BLOOD-COAGULATION; THROMBIN GENERATION; EXTRINSIC PATHWAY; PLASMA FACTOR; FACTOR-IX; HEMOSTASIS; INHIBITOR; MODEL;
D O I
10.1111/j.1365-2516.2011.02638.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Haemophilia A individuals displaying a similar genetic defect have heterogeneous clinical phenotypes. Our objective was to evaluate the underlying effect of exogenous factor (f)VIII on tissue factor (Tf)-initiated blood coagulation in severe haemophilia utilizing both empirical and computational models. We investigated twenty-five clinically severe haemophilia A patients. All individuals were on fVIII prophylaxis and had not received fVIII from 0.25 to 4 days prior to phlebotomy. Coagulation was initiated by the addition of Tf to contact-pathway inhibited whole blood +/- an anti-fVIII antibody. Aliquots were quenched over 20 min and analyzed for thrombin generation and fibrin formation. Coagulation factor levels were obtained and used to computationally predict thrombin generation with fVIII set to either zero or its value at the time of the draw. As a result of prophylactic fVIII, at the time of the blood draw, the individuals had fVIII levels that ranged from <1% to 22%. Thrombin generation (maximum level and rate) in both empirical and computational systems increased as the level of fVIII increased. FXIII activation rates also increased as the fVIII level increased. Upon suppression of fVIII, thrombin generation became comparable in both systems. Plasma composition analysis showed a negative correlation between bleeding history and computational thrombin generation in the absence of fVIII. Residual prophylactic fVIII directly causes an increase in thrombin generation and fibrin cross-linking in individuals with clinically severe haemophilia A. The combination of each individuals coagulation factors (outside of fVIII) determine each individuals baseline thrombin potential and may affect bleeding risk.
引用
收藏
页码:193 / 199
页数:7
相关论文
共 50 条
  • [41] Clinical application of extended half-life factor VIII in children with severe haemophilia A
    Dettoraki, Athina
    Michalopoulou, Aikaterini
    Mazarakis, Michalis
    Saslis, Stefanos
    Stamati, Ioanna
    Kapsimali, Zoey
    Pergantou, Helen
    HAEMOPHILIA, 2022, 28 (04) : 619 - 624
  • [42] Haemarthrosis and arthropathy do not favour the development of factor VIII inhibitors in severe haemophilia A mice
    Peyron, I.
    Dimitrov, J. D.
    Delignat, S.
    Gangadharan, B.
    Planchais, C.
    Kaveri, S. V.
    Lacroix-Desmazes, S.
    HAEMOPHILIA, 2015, 21 (01) : E94 - E98
  • [43] Immune system polymorphisms and factor VIII inhibitor formation in Brazilian haemophilia A severe patients
    Agostini, D.
    Rosset, C.
    Botton, M. R.
    Kappel, D. B.
    Vieira, I. A.
    Gorziza, R. P.
    Salzano, F. M.
    Bandinelli, E.
    HAEMOPHILIA, 2012, 18 (06) : e416 - e418
  • [44] Evaluation of nonneutralizing antibodies against factor VIII in severe haemophilia A patients from India
    David, Sachin
    Mathews, Nitty S.
    Singh, G. Surender
    Korula, Anu
    Aboobacker, Fouzia Nambiatheyil
    Abraham, Aby
    George, Biju
    Srivastava, Alok
    Mathews, Vikram
    Nair, Sukesh C.
    BLOOD COAGULATION & FIBRINOLYSIS, 2019, 30 (07) : 337 - 340
  • [45] Quality Of Life And Satisfaction Of Adults With Haemophilia A Switched To Prophylactic Treatment With Recombinant Factor VIII Turoctocog Alfa
    Ozelo, M.
    Meunier, J.
    Hoxer, C. S.
    Slothuus, U.
    HAEMOPHILIA, 2015, 21 : 67 - 68
  • [46] The impact of prophylactic treatment on children with severe haemophilia
    Liesner, RJ
    Khair, K
    Hann, IM
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 92 (04) : 973 - 978
  • [47] Update of the risk of inhibitor occurrence at first treatment by a Factor VIII concentrate in severe haemophilia A
    Chambost, H.
    Guillaume, Y.
    Falaise, C.
    Roux, C.
    Monpoux, F.
    REVUE D ONCOLOGIE HEMATOLOGIE PEDIATRIQUE, 2015, 3 (02): : 78 - 87
  • [48] Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia
    Mathias, M
    Khair, K
    Hann, I
    Liesner, R
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (03) : 366 - 368
  • [49] Impact of a nursing home support program for prophylactic factor administration in children with severe haemophilia
    Bruce, Aisha
    Corriveau-Bourque, Catherine
    Greenslade, Haley
    Gibbs, Teresa
    Belletrutti, Mark
    Bauman, Heather
    HAEMOPHILIA, 2018, 24 : 129 - 129
  • [50] Pathophysiology of inhibitors to factor VIII in patients with haemophilia A
    Lacroix-Desmazes, S
    Misra, N
    Bayry, J
    Artaud, C
    Drayton, B
    Kaveri, SV
    Kazatchkine, MD
    HAEMOPHILIA, 2002, 8 (03) : 273 - 279